Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Launched by GLAUKOS CORPORATION · Mar 29, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called corneal cross-linking for people with a condition known as keratoconus, which causes the cornea (the front part of the eye) to become thin and bulge. The goal of the study is to find out if this treatment is safe and effective for those who have progressive keratoconus, meaning their condition is getting worse over time. If you or someone you know has been diagnosed with keratoconus and is between the ages of 6 and 20, you might be eligible to participate in this trial.

Participants will need to provide consent, meaning they agree to take part in the study and understand what it involves. They should be able to keep their gaze steady during the tests and follow the doctor’s instructions for follow-up visits. However, those with allergies to the treatment materials or other eye conditions unrelated to keratoconus may not qualify. If you join the study, you can expect to undergo the corneal cross-linking procedure and be monitored closely to assess how well it works and if there are any side effects. This trial is currently recruiting participants, so it's a good opportunity to help advance treatment options for keratoconus.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provide written informed consent
• • Ability to hold gaze sufficiently stable for study testing
• • Willingness and ability to follow all instructions and comply with schedule for follow-up visits
• • Have a diagnosis of keratoconus
• Exclusion Criteria:
• • Known allergy or sensitivity to the test articles or components
• • Any disease causing abnormal topography other than keratoconus
• • Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications